EP3113771A4 - Therapeutic uses of ibogaine and related compounds - Google Patents

Therapeutic uses of ibogaine and related compounds Download PDF

Info

Publication number: EP3113771A4
Authority: EP; European Patent Office
Prior art keywords: ibogaine; related compounds; therapeutic uses; therapeutic; compounds
Prior art date: 2014-03-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP15758129.9A

Other languages

German (de)

French (fr)

Other versions

EP3113771A1 (en

Inventor

Emeline Maillet

Lawrence Friedhoff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

DemeRx Inc

Original Assignee

DemeRx Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-03

Filing date

2015-03-02

Publication date

2017-10-25

2015-03-02 Application filed by DemeRx Inc filed Critical DemeRx Inc

2017-01-11 Publication of EP3113771A1 publication Critical patent/EP3113771A1/en

2017-10-25 Publication of EP3113771A4 publication Critical patent/EP3113771A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse

Landscapes

Health & Medical Sciences (AREA)
Addiction (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP15758129.9A 2014-03-03 2015-03-02 Therapeutic uses of ibogaine and related compounds Withdrawn EP3113771A4 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US201461947397P	2014-03-03	2014-03-03
US201461952724P	2014-03-13	2014-03-13
US201461952743P	2014-03-13	2014-03-13
US201461952736P	2014-03-13	2014-03-13
US201461952725P	2014-03-13	2014-03-13
US201461952740P	2014-03-13	2014-03-13
US201461952718P	2014-03-13	2014-03-13
US201462049968P	2014-09-12	2014-09-12
PCT/US2015/018356 WO2015134405A1 (en)	2014-03-03	2015-03-02	Therapeutic uses of ibogaine and related compounds

Publications (2)

Publication Number	Publication Date
EP3113771A1 EP3113771A1 (en)	2017-01-11
EP3113771A4 true EP3113771A4 (en)	2017-10-25

Family

ID=54055765

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15758129.9A Withdrawn EP3113771A4 (en)	2014-03-03	2015-03-02	Therapeutic uses of ibogaine and related compounds

Country Status (4)

Country	Link
EP (1)	EP3113771A4 (en)
AU (2)	AU2015225442A1 (en)
CA (2)	CA2978537C (en)
WO (1)	WO2015134405A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9561233B2 (en)	2014-03-13	2017-02-07	Demerx, Inc.	Use of ibogaine for the treatment of pain
US9592239B2 (en)	2014-09-12	2017-03-14	Demerx, Inc.	Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US20220169668A1 (en)	2019-04-17	2022-06-02	Compass Pathfinder Limited	Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN114786677A (en) *	2019-10-01	2022-07-22	思维医学股份有限公司	18-MC for the treatment of substance use disorders
CN115916215A (en) *	2020-04-16	2023-04-04	长矛治疗股份有限公司	Transdermal microdosing delivery of hallucinogen derivatives
WO2023278108A1 (en) *	2021-06-29	2023-01-05	Mind Medicine, Inc.	18-mc for treating obesity
WO2024171075A1 (en) *	2023-02-15	2024-08-22	Clearmind Medicine Inc.	Compositions comprising ibogaine, optionally in combination with n-acylethanolamines, and uses thereof
WO2024254701A1 (en) *	2023-06-16	2024-12-19	Ambio Life Sciences Inc.	Ibogaine for the treatment of multiple sclerosis
WO2025000092A1 (en) *	2023-06-28	2025-01-02	Ambio Life Sciences Inc.	Ibogaine treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4857523A (en) *	1988-07-18	1989-08-15	Nda International, Inc.	Rapid method for attenuating the alcohol dependency syndrome

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5629307A (en) *	1989-10-20	1997-05-13	Olney; John W.	Use of ibogaine in reducing excitotoxic brain damage
WO2008039179A1 (en) *	2006-09-26	2008-04-03	Addiction Research Institute, Inc.	Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c

2015
- 2015-03-02 AU AU2015225442A patent/AU2015225442A1/en not_active Abandoned
- 2015-03-02 CA CA2978537A patent/CA2978537C/en active Active
- 2015-03-02 CA CA3212001A patent/CA3212001A1/en active Pending
- 2015-03-02 WO PCT/US2015/018356 patent/WO2015134405A1/en active Application Filing
- 2015-03-02 EP EP15758129.9A patent/EP3113771A4/en not_active Withdrawn
2020
- 2020-11-18 AU AU2020273281A patent/AU2020273281B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4857523A (en) *	1988-07-18	1989-08-15	Nda International, Inc.	Rapid method for attenuating the alcohol dependency syndrome

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMIR H. REZVANI ET AL: "Attenuation of alcohol intake by Ibogaine in three strains of alcohol-preferring rats", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR., vol. 52, no. 3, 1 November 1995 (1995-11-01), US, pages 615 - 620, XP055223408, ISSN: 0091-3057, DOI: 10.1016/0091-3057(95)00152-M *
DEBORAH C. MASH ET AL: "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 914, no. 1, 1 September 2000 (2000-09-01), US, pages 394 - 401, XP055407277, ISSN: 0077-8923, DOI: 10.1111/j.1749-6632.2000.tb05213.x *
JONATHAN CACHAT ET AL: "Unique and potent effects of acute ibogaine on zebrafish: The developing utility of novel aquatic models for hallucinogenic drug research", BEHAVIOURAL BRAIN RESEARCH., vol. 236, 1 January 2013 (2013-01-01), NL, pages 258 - 269, XP055407280, ISSN: 0166-4328, DOI: 10.1016/j.bbr.2012.08.041 *
KENNETH R. ALPER ET AL: "Treatment of Acute Opioid Withdrawal with Ibogaine", AMERICAN JOURNAL OF ADDICTIONS, vol. 8, no. 3, 1 January 1999 (1999-01-01), US, pages 234 - 242, XP055223410, ISSN: 1055-0496, DOI: 10.1080/105504999305848 *
KOENIG XAVER ET AL: "Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: A study to assess the drug's cardiac ion channel profile", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 273, no. 2, 22 May 2013 (2013-05-22), pages 259 - 268, XP028784922, ISSN: 0041-008X, DOI: 10.1016/J.TAAP.2013.05.012 *

Also Published As

Publication number	Publication date
AU2020273281B2 (en)	2024-05-02
WO2015134405A1 (en)	2015-09-11
EP3113771A1 (en)	2017-01-11
AU2020273281A1 (en)	2020-12-17
CA3212001A1 (en)	2015-09-11
CA2978537A1 (en)	2015-09-11
AU2015225442A1 (en)	2016-10-20
CA2978537C (en)	2023-10-24

Publication	Publication Date	Title
EP3504213A4 (en)	2020-01-15	Amino-pyrrolopyrimidinone compounds and methods of use thereof
HK1243073A1 (en)	2018-07-06	Therapeutic compounds and uses thereof
EP3377070A4 (en)	2019-07-10	Compounds and methods of their use
EP3245291A4 (en)	2018-09-19	Novel micro-dystrophins and related methods of use
EP3199628A4 (en)	2018-06-06	Cytotoxicity-inducing therapeutic agent
EP3218005A4 (en)	2018-09-12	Glycan-interacting compounds and methods of use
GB201403093D0 (en)	2014-04-09	Therapeutic compounds and their use
EP3102200A4 (en)	2017-07-05	Therapeutic compounds and compositions
EP3177638A4 (en)	2018-01-17	Targeting peptides and methods of use
EP3116898A4 (en)	2017-08-30	Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
EP3113771A4 (en)	2017-10-25	Therapeutic uses of ibogaine and related compounds
EP3116511A4 (en)	2017-10-18	Compositions of selenoorganic compounds and methods of use thereof
EP3134088A4 (en)	2017-09-13	Bicylcic pyrazolone compounds and methods of use
EP3240576A4 (en)	2018-06-20	Methods of transdifferentiation and methods of use thereof
EP3188721A4 (en)	2018-05-02	Human therapeutic agents
EP3526205A4 (en)	2020-05-27	Therapeutic compounds and methods of use thereof
EP3217992A4 (en)	2018-07-18	Probiotic therapeutic applications
EP3117827A4 (en)	2017-12-20	Composition for vagina and use of the composition
EP3190886A4 (en)	2018-04-25	Compositions and methods of use thereof
EP3107546A4 (en)	2017-10-25	Therapeutic methods employing noribogaine and related compounds
EP3231793A4 (en)	2018-09-19	Dihydropyrimidine-2-one compounds and medicinal uses thereof
EP3229813A4 (en)	2018-07-25	Treatment of hmgb1-mediated inflammation
EP3384921A4 (en)	2019-08-14	New use of thiopeptin
EP3297619A4 (en)	2019-01-02	Therapeutic uses of l-4-chlorokynurenine
EP3134108A4 (en)	2018-01-17	Agents and methods of treatment

Legal Events

Date	Code	Title	Description
2016-11-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2016-12-09	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-12-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-01-11	17P	Request for examination filed	Effective date: 20161003
2017-01-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-01-11	AX	Request for extension of the european patent	Extension state: BA ME
2017-06-07	DAV	Request for validation of the european patent (deleted)
2017-06-07	DAX	Request for extension of the european patent (deleted)
2017-10-25	A4	Supplementary search report drawn up and despatched	Effective date: 20170926
2017-10-25	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/32 20060101ALI20170920BHEP Ipc: A61K 31/404 20060101ALI20170920BHEP Ipc: A61P 25/34 20060101ALI20170920BHEP Ipc: A61P 25/36 20060101ALI20170920BHEP Ipc: A61K 31/55 20060101AFI20170920BHEP Ipc: A61P 25/30 20060101ALI20170920BHEP Ipc: A61K 31/4738 20060101ALI20170920BHEP
2018-09-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2018-10-31	18D	Application deemed to be withdrawn	Effective date: 20180424